These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35007145)

  • 61. [Combination and sequential therapy using bisphosphonates.].
    Okazaki R
    Clin Calcium; 2017; 27(2):263-271. PubMed ID: 28123129
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Osteoporosis.
    Ensrud KE; Crandall CJ
    Ann Intern Med; 2017 Aug; 167(3):ITC17-ITC32. PubMed ID: 28761958
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Risk adapted treatment of osteoporosis].
    Schute L
    Dtsch Med Wochenschr; 2011 Jul; 136(27):1440; author reply 1440. PubMed ID: 21713725
    [No Abstract]   [Full Text] [Related]  

  • 64. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
    McClung M
    Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Minodronate for the treatment of osteoporosis.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
    Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Practical Approach to Children with Recurrent Fractures.
    Korula S; Titmuss AT; Biggin A; Munns CF
    Endocr Dev; 2015; 28():210-225. PubMed ID: 26138844
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
    Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
    Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Oral bisphosphonates and atrial fibrillation.
    Majumdar SR
    BMJ; 2008 Apr; 336(7648):784-5. PubMed ID: 18334526
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost‏.
    Chodick G; Moser SS; Goldshtein I
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):359-70. PubMed ID: 27015247
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?
    Black DM; Bauer DC; Schwartz AV; Cummings SR; Rosen CJ
    N Engl J Med; 2012 May; 366(22):2051-3. PubMed ID: 22571169
    [No Abstract]   [Full Text] [Related]  

  • 71. Fracture risk is under-recognised and under-treated in memory clinic attendees.
    Lampshire Z; Tingley D; Jarvis A; Wernham C; Hughes JC; Welsh TJ
    Maturitas; 2019 May; 123():37-39. PubMed ID: 31027675
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bisphosphonates for osteoporosis--where do we go from here?
    Whitaker M; Guo J; Kehoe T; Benson G
    N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168
    [No Abstract]   [Full Text] [Related]  

  • 73. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
    Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Ikumi N; Sugiyama K; Nagasawa Y; Karasawa H; Iwata M; Matsukawa Y; Takei M
    Int J Rheum Dis; 2018 Apr; 21(4):813-820. PubMed ID: 26929019
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Bisphosphonates (BP) and osteonecrosis of the jaws; continuous treatment with Bisphosphonates should be considered].
    Mawatari T
    Clin Calcium; 2010 Nov; 20(11):1743-7. PubMed ID: 21066910
    [No Abstract]   [Full Text] [Related]  

  • 77. [Efficacy and safety of long-term bisphosphonate treatment for osteoporosis.].
    Miki T
    Clin Calcium; 2017; 27(2):239-246. PubMed ID: 28123126
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bisphosphonate therapy: how long is long enough?
    McClung MR
    Osteoporos Int; 2015 May; 26(5):1455-7. PubMed ID: 25609156
    [No Abstract]   [Full Text] [Related]  

  • 79. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
    Bobba R; Adachi JD
    Clin Interv Aging; 2007; 2(3):275-82. PubMed ID: 18044178
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis.
    Suzuki A; Sekiguchi S; Asano S; Itoh M
    J Pharmacol Sci; 2008 Apr; 106(4):530-5. PubMed ID: 18431035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.